tiprankstipranks
Trending News
More News >

SymBio Pharmaceuticals Reports Significant Financial Decline in FY 2024

Story Highlights
SymBio Pharmaceuticals Reports Significant Financial Decline in FY 2024

Confident Investing Starts Here:

Symbio Pharmaceuticals Limited ( (JP:4582) ) just unveiled an update.

SymBio Pharmaceuticals Limited reported a significant decline in financial performance for the fiscal year 2024, with net sales falling by 56.1% and a substantial increase in net loss compared to the previous year. The company continues to face challenges, including a decrease in total assets and cash equivalents, while planning a new subsidiary in the USA, which may impact its future operations and market positioning.

More about Symbio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on developing and commercializing oncology and rare disease therapies.

YTD Price Performance: -8.54%

Average Trading Volume: 304,634

Technical Sentiment Consensus Rating: Buy

Current Market Cap: Yen8.34B

For a thorough assessment of 4582 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1